Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 2
2007 1
2008 2
2009 2
2010 1
2012 1
2013 2
2014 1
2015 3
2016 8
2017 3
2018 4
2019 2
2020 1
2021 8
2022 7
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G, Dell'Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, Barlati S, Rosso G, Di Nicola M, Marcatili M, d'Andrea G, Cavallotto C, Chiappini S, De Filippis S, Nicolò G, De Fazio P, Andriola I, Zanardi R, Nucifora D, Di Mauro S, Bassetti R, Pettorruso M, McIntyre RS, Sensi SL, di Giannantonio M, Vita A; REAL-ESK Study Group. Martinotti G, et al. Among authors: de filippis s. Bipolar Disord. 2023 May;25(3):233-244. doi: 10.1111/bdi.13296. Epub 2023 Jan 18. Bipolar Disord. 2023. PMID: 36636839 Free article.
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
Pettorruso M, Guidotti R, d'Andrea G, De Risio L, D'Andrea A, Chiappini S, Carullo R, Barlati S, Zanardi R, Rosso G, De Filippis S, Di Nicola M, Andriola I, Marcatili M, Nicolò G, Martiadis V, Bassetti R, Nucifora D, De Fazio P, Rosenblat JD, Clerici M, Maria Dell'Osso B, Vita A, Marzetti L, Sensi SL, Di Lorenzo G, McIntyre RS, Martinotti G; REAL-ESK Study Group. Pettorruso M, et al. Among authors: de filippis s. Psychiatry Res. 2023 Sep;327:115378. doi: 10.1016/j.psychres.2023.115378. Epub 2023 Jul 28. Psychiatry Res. 2023. PMID: 37574600 Free article.
Future drugs for migraine.
Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Farinelli I, et al. Among authors: de filippis s. Intern Emerg Med. 2009 Oct;4(5):367-73. doi: 10.1007/s11739-009-0273-0. Epub 2009 Jun 24. Intern Emerg Med. 2009. PMID: 19551474 Review.
Identification of clinical phenotypes in schizophrenia: the role of lurasidone.
Riva MA, Albert U, de Filippis S, Vita A, De Berardis D. Riva MA, et al. Among authors: de filippis s. Ther Adv Psychopharmacol. 2021 May 10;11:20451253211012250. doi: 10.1177/20451253211012250. eCollection 2021. Ther Adv Psychopharmacol. 2021. PMID: 34025981 Free PMC article. Review.
Genetics of migraine and pharmacogenomics: some considerations.
Piane M, Lulli P, Farinelli I, Simeoni S, De Filippis S, Patacchioli FR, Martelletti P. Piane M, et al. Among authors: de filippis s. J Headache Pain. 2007 Dec;8(6):334-9. doi: 10.1007/s10194-007-0427-2. Epub 2007 Dec 5. J Headache Pain. 2007. PMID: 18058067 Free PMC article. Review.
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
Chiappini S, d'Andrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, Barlati S, Pettorruso M, Sensi S, Clerici M, Dell'Osso B, Vita A, Martinotti G. Chiappini S, et al. Among authors: de filippis s. Eur Neuropsychopharmacol. 2023 Sep;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011. Epub 2023 May 4. Eur Neuropsychopharmacol. 2023. PMID: 37148637 Free article.
55 results